MiNK Therapeutics (INKT)

• Market cap: $54.1M
• 1 day: -1.76%
• 5 days: -2.12%
• 1 month: -13.11%
• 3 months: -4.25%
• 6 months: -8.62%
• Year to date: -4.68%
• 1 year: -17.25%
• 5 years: -94.42%
• 10 years: -91.17%
• Sector: Healthcare
• Industry: Biotechnology

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Employees: 15